Journal Mobile Options
Table of Contents
Vol. 21, No. 4, 2001
Issue release date: July–August 2001

Long-Term Impact of Hepatitis B, C Virus Infection on Renal Transplantation

Lee W.-C. · Shu K.-H. · Cheng C.-H. · Wu M.-J. · Chen C.-H. · Lian J.-C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Chronic liver disease and its complications are major problems in renal transplant recipients. Our aim was to elucidate the influence of hepatitis B, C virus infection on the long-term outcome of renal transplantation. Four hundred and seventy-seven patients who received renal transplantation between January 1984 and December 1999, and who were followed up at our hospital were enrolled. HBsAg was detected by the RIA method and anti-HCV Ab was assayed by the second-generation RIA kit. SGOT/ SGPT were checked every 3 months. Hepatoma was diagnosed by dynamic CT scan, elevated α-fetoprotein, hypervascularity by angiography and confirmed by pathological examination. The prevalence of HBV, HCV, coinfected HBV/HCV was 9.9% (n = 47), 28.5% ( n = 136), 3.1% (n = 15), respectively. The incidences of hepatoma in the HBV–/HCV–, HBV–/HCV+, HBV+/HCV–, HBV+/HCV+ groups were 1.4% (n = 4), 4.4% (n = 6), 6.4% (n = 3), 6.7% (n = 1), respectively (p = 0.114). The incidences of liver cirrhosis/hepatic failure were 3.2% (n = 9) , 6.6% (n = 9) , 21.3% (n = 10) , 20% (n = 3), respectively (p < 0.001). The frequencies of chronic liver disease were 10.4% (n = 29) , 45.6% (n = 62) , 66% (n = 31) , 80% (n = 12), respectively (p < 0.001). Patient and graft survival rates were lower in the HBV-infected group than in the other groups. Cox regression analysis revealed that HBV infection is likely an independent risk factor for patient mortality although the statistical significance was only borderline. Patients with HBV as well as HCV infection were not at risk of graft loss according to this model of analysis. Patients with HBV infection showed higher incidences of hepatoma, hepatic failure, graft failure and death. Therefore, HBV-infected patients who are candidates for renal transplantation should be carefully evaluated. It seems that HCV infection has little influence on the outcome of renal transplant recipients. A longer period of follow-up is needed to clarify the impact of HCV on renal transplant recipients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rao KV, Andersen RC: Long-term results and complications in renal transplant recipients. Transplantation 1988;45:45–52.
  2. Rodicio JL, Morales JM: Liver disease in renal transplant recipients; in Massry SG, Glassock RJ (eds): Textbook of Nephrology. Baltimore, Williams & Wilkins, 1995, pp 1684–1689.
  3. Pirson Y, Alexandre GP, van Ypersele de Strihou C: Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977;296:194–196.

    External Resources

  4. Huang CC, Liaw YF, Lai MK, Chu SH, Chuang CK, Huang JY: The clinical outcome of hepatitis C virus Ab-positive renal allograft recipients. Transplantation 1992;53:763–765.

    External Resources

  5. Roth D, Zucker K, Cirocco R, DeMattos A, Burke GW, Nery J, Esquenazi V, Babischkin S, Miller J: The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994;45:238–244.
  6. Hu RH, Lee PH, Chung YC, Huang MT, Lee CS: Hepatitis B and C in renal transplantation in Taiwan. Transplant Proc 1994;26:2059–2061.
  7. Harnett JD, Zeldis JB, Parfrey PS, Kennedy M, Sircar R, Steinmann TI, Guttmann RD: Hepatitis B disease in dialysis and transplant patients: Further, epidemiologic and serologic studies. Transplantation 1987;44:369–376.
  8. Huang CC: Hepatitis in patients with end stage renal disease. J Gastroenterol 1997;12(suppl):S236–241.
  9. Huang CC: Dialysis therapy in Taiwan: 1995 national surveillance report. J Nephrol ROC 1995;9:71–83.
  10. Platt JF: Noninvasive imaging of the liver and biliary system; in Schiff ER, Sorvell MF, Maddrey WC (eds): Schiff’s diseases of the liver. Philadelphia, Lippincott-Raven, 1999, pp 267–290.
  11. Okuda K, Okuda H: Primary liver cell carcinoma; in Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J (eds): Oxford Textbook of Clinical Hepatology. Oxford, Oxford Medical Publications, 1999, pp 1492–1530.
  12. Ponz E, Campistol J.M, Bruguerua M, Barrera JM, Gil C, Pinto JB, Andreu J: Hepatitis C virus infection among kidney transplant recipients. Kidney Int 1991;40:748–751.
  13. Jeffers LJ, Perez GO, de Medina MD, Ortiz Interian CJ, Schiff ER, Reddy KR, Jimenez M, Bourgoignie JJ, Vaamonde CA, Duncan R: Hepatitis C infection in two urban hemodialysis units. Kidney Int 1990;38:320–322.
  14. Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S: Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998;66:471–476.

    External Resources

  15. Sung JL: Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12(suppl):S370–S376.
  16. Rao KV, Kasiske BL, Anderson WR: Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B positive and B negative renal transplant recipients. Transplantation 1991;51:391–396.

    External Resources

  17. Hillie WD, Hillis A, Walker WG: Hepatitis B surface antigenemia in renal transplant recipients. JAMA 1979;242:329–332.
  18. Parfrey PS, Forbes RD, Hutchinson TA, Beaudoin JG, Dauphinee WD, Hollomby DJ, Guttmann RD: The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 1984;37:461–466.
  19. Kim YS, Kim SI, Suh JS, Chon CY, Park K: Renal transplantation is not contraindicated in hepatitis B surface antigen positive patients. Transplant Proc 1992;24:1541–1542.
  20. Tang S, Lo CM, Chan TM, Lai KN: Early detection of hepatocellular carcinoma in hepatitis B-positive renal transplant recipients. J Surg Oncol 1999;72:99–101.
  21. Pol S, Debure A, Degott C, Carnot F, Legendre C, Brechot C, Kreis H: Chronic hepatitis in kidney allograft recipients. Lancet 1990;335:878–880.
  22. Schweitzer EJ, Bartlett ST, Keay S, Hadley GA, Cregar J, Stockdreher DD: Impact of hepatitis B or C infection on the practice of kidney transplantation in the United States. Transplant Proc 1993;25:1456–1457.

    External Resources

  23. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO: Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257–263.
  24. Stempel CA, Lake J, Kuo G, Vincenti F: Hepatitis C – its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993;55:273–276.

    External Resources

  25. Legendre C, Garrigue V, Le Bihan C, Mamzer Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S: Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998;65:667–670.

    External Resources

  26. Penn I: Malignancy. Surg Clin North Am 1994;74:1247–1257.
  27. Yang TC, Shu KH, Cheng CH, Wu MJ, Lian JD: Malignancy following renal transplantation. Chung Hua I Hsueh Tsa Chih (Taipei) 1998;61:281–288.
  28. Isselbacher JK, Dienstag JL: Tumors of the liver and biliary tract; in Fauci AS (ed): Harrison’s Principles of Internal Medicine. New York, McGraw-Hill, 1996, pp 578–581.
  29. Koike K, Yasuda K, Yotsuyanagi H, Moriya K, Hino K, Kurokawa K, Iino S: Dominant replication of either virus in dual infection with hepatitis virus B and C. J Med Virol 1995;45:236–239.

    External Resources

  30. Liaw YF, Tsai SL, Chang JJ, Sheen IS, Chien RN, Lin DY, Chu CM: Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994;106:1048–1053.
  31. Corell A, Morales JM, Mandrono A, Munoz MA, Andres A, Fuertes A, Arnaiz Villena A: Immunosuppression induced by hepatitis C virus infection reduces acute renal-transplant rejection. Lancet 1995;346:1497–1498.
  32. Knoli GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ: The impact of renal transplantation on survival in hepatitis C positive end stage renal disease patients. Am J Kidney Dis 1997;29:608–614.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50